Resources

Engitix announced the appointment of Sonia Quaratino, MD, PhD in the newly created role of Executive Vice President (EVP) Chief Medical Officer (CMO).

Analysis for Innovators (A4I) is a funding programme that helps UK SMEs overcome complex measurement, testing and analysis challenges by providing access to world-class expertise, specialist facilities and scientific knowledge from leading UK measurement organisations, including NML.

Coulter Partners, the global advisor building leadership teams for Health, Science and Technology innovation businesses, today announces the appointment of Carlos Gómez-Arnau, Doug Roberts, and Stuart Penney as Client Partners. These strategic hires further strengthen the firm's international presence and reinforce its commitment to supporting clients across key healthcare, life sciences, and biotechnology markets.

New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs

The NML has published its Annual Review 2025, reflecting on a year of scientific achievement, collaboration and investment in the future of UK chemical and biological measurement science. The Review showcases how the NML’s trusted measurement expertise is enabling innovation to be translated into real-world impact, supporting UK growth and regional expertise, and strengthening public confidence in policy and government decisions. If you would like to discuss any of the work featured in this Review or explore future collaboration opportunities with the NML, please contact [email protected]

Precision BioSearch partners with Cytospire Therapeutics to appoint Sumeet Ambarkhane as CMO

Stevenage Bioscience Catalyst Board appoints Andrew Waters as Chief Executive Officer

Tangram Therapeutics announces progression to patient cohorts in Phase 1/2 RESTORE-MASH trial of TGM-312 and appointment of Dr Sonya Montgomery as Chief Development Officer

Coulter Partners successfully led a search assignment for NRG Therapeutics Ltd. and is pleased to announce the placement of Claus Sundgreen, M.D. as Chief Medical Officer (CMO).

Foventa has strengthened its management team with a new CMO Dr Zaiba Malik and CFO Julia Jones as the company prepares for a Series A funding round to take lead asset FOV407 into a Phase IIb trial.

Imagine a world where diabetic patients no longer lose their sight. Foventa are already trialling a simple eyedrop that could make this a reality. Previously Exonate, Foventa are now Phase II ready and about to commence a Series A funding round.

Opening for participation on September 2nd 2026, PIR International’s 2027 EU/UK Biotech & Life Sciences Board Remuneration & Diversity Study will provide a comprehensive, data-driven view of board remuneration, composition and diversity across the European and UK life sciences sector.

Agilent Technologies has been announced as a founding member of Harwell’s new CO:LABS development.

Chris Molloy on Mike Hoare, the RedX-Skye deal, Stablepharma’s fridge-free vaccine, MHRA quarterly numbers, ministerial responsibilities for UK life sciences and human biology-based models

BIA Annual General Meeting 2026: nominations open for BIA Board election

The advantages to building a business in the UK's biotech clusters

Last month, the multi-award-winning Advanced Therapies Apprenticeship Community (ATAC) welcomed its 400th member. 

NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company developing novel disease-modifying therapeutics that rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce the appointment of Claus Sundgreen M.D. as chief medical officer (CMO), effective 1 August 2026.

ELRIG has appointed Drs Hitesh Sanganee and Marcus Schindler to its Scientific Advisory Board (SAB).

The Milner Therapeutics Institute has joined the o2h Discovery Platinum Partner Programme, enabling eligible companies within its bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award.